# Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

> **NCT00657904** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3618 (actual)

## Conditions studied

- Non-metastatic Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00657904
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 3618 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657904, "Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00657904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*